Scarica l'app Stockscreener
120.14
0.10%
0.12
Dopo l'orario di chiusura:
120.50
0.36
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead, J&J Pare Case on Laurus Copy of HIV Drug to Two Patents - Bloomberg Law News
Gilead stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
Gilead Sciences stock hits 52-week high at 121.67 USD By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at 121.67 USD - Investing.com
Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating - TipRanks
Stock Analysis | Gilead Sciences OutlookA Mixed Picture Amid Volatile Technicals - AInvest
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus - TradingView
Gilead Sciences’ Earnings Call Highlights Growth and Strategic Advances - TipRanks
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir - Insider Monkey
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here - MSN
Gilead Sciences Explores New Dosing for Triple-Negative Breast Cancer Treatment - TipRanks
Gilead Sciences’ Phase 3 Study on Sacituzumab Govitecan: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Deutsche Bank Adjusts Gilead Sciences Price Target to $135 From $120, Maintains Buy Rating - MarketScreener
Kymera Revenue Drops 55 Percent in Q2 - The Motley Fool
Factory fallout: Manufacturing plant closures and layoffs from Dow, Gilead Sciences, Whitford, and more - Plant Services
Gilead drops Novo Nordisk-partnered liver disease candidate - medwatch.com
Gilead Sciences soars on strong HIV drug sales - medwatch.com
Gilead Sciences (GILD) Is Up 5.5% After Earnings Beat and EU Lenacapavir Milestone – What's Changed - simplywall.st
Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. - MSN
Gilead Stock Is Closing In on an All-Time High. The Case for More Upside. - Barron's
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating - TipRanks
Gilead Sciences’ Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency - Insider Monkey
Gilead Sciences Inc. Recovery Hinges on Volume BreakoutRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Gilead Sciences' Strategic Momentum with Yeztugo and HIV Portfolio Growth: A Cornerstone for Long-Term Value Creation - AInvest
Gilead Sciences: A Resilient HIV Franchise and Strategic Catalysts for Long-Term Growth - AInvest
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish - MSN
The Gilead Sciences, Inc. (NASDAQ:GILD) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences (GILD) Rises on Raised 2025 Guidance and $6B Buyback Is Its Outlook Reinvigorated? - simplywall.st
Gilead trims assets partnered with Novo Nordisk, Arcus from pipeline - firstwordpharma.com
Gilead Sciences Surges 8.28% On Bullish Breakout With Heavy Volume - AInvest
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results - FinancialContent
These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More - Barron's
Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP - Investor's Business Daily
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook - Invezz
Gilead Rallies: Bullish Surge Continues! - timothysykes.com
Gilead Sciences stock price target raised to $140 from $126 at BofA - Investing.com
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Gains Ground As Gilead Sciences Soars 8% - FXEmpire
Gilead Sciences jumps after Q2 beat; Truist upgrades to Buy - MSN
Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 - geneonline.com
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results - FinancialContent
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details - The Economic Times
Gilead’s Yeztugo sales “ahead of expectations” following launch - Yahoo Finance
Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology? - TipRanks
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today - Yahoo Finance
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Gilead Sciences Stock Surges 9% on Strong Q2 Earnings - AInvest
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
Gilead culls Novo-partnered MASH candidate and 2 cancer assets - Fierce Biotech
Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales - Fierce Pharma
Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk - Morningstar
Why Is Gilead Sciences Stock Surging Friday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead's Optimistic Relaxed CAR T Safety Monitoring Could Help Sluggish Yescarta, Tecartus Q2 Sales - Precision Medicine Online
Gilead Sciences: Is There Momentum to Sustain Market Buzz? - StocksToTrade
Shareholders strongly echo Gilead’s successful quarter claims - The Pharma Letter
Gilead Sciences stock price target raised to $98 from $96 at RBC Capital - Investing.com
Truist Securities Upgrades Gilead Sciences to Buy From Hold, Hikes Price Target to $127 From $108 - MarketScreener
UBS Raises Price Target on Gilead Sciences to $112 From $108, Maintains Neutral Rating - MarketScreener
Gilead Sciences stock price target raised to $115 from $110 at TD Cowen - Investing.com Canada
Gilead Sciences Reports Strong Q2 Earnings, Beats Wall Street EstimatesNews and Statistics - IndexBox
Baird Adjusts Price Target on Gilead Sciences to $108 From $100, Maintains Neutral Rating - MarketScreener
JPMorgan Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Overweight Rating - MarketScreener
BMO Capital Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Outperform Rating - MarketScreener
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant - Stocktwits
Goldman Sachs Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Neutral Rating - MarketScreener
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties - BioSpace
2.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):